A Novel Aspergillus Galactomannan Chemiluminescence Immunoassay: Evaluation for Diagnosis of Invasive Pulmonary Aspergillosis in a Multicenter Controlled Study.

GM-CLIA demonstrates high sensitivity (93.97% in serum, 93.58% in BALF) and specificity (97.46% in serum, 95.76% in BALF) for diagnosing invasive aspergillosis in serum and BALF samples.

• Why it matters: Accurate, rapid, non-culture-based diagnostic tools are needed to improve invasive aspergillosis detection and patient outcomes, addressing limitations of current methods.
• What they did: The study evaluated 246 serum and 228 BALF samples from 229 IA patients and 236 non-IA patients using GM-CLIA, comparing its performance with GM-EIA through correlation, ROC, and other analytical tests.
• The result: GM-CLIA showed high diagnostic accuracy with ROC AUC values of 0.977 (serum) and 0.982 (BALF), and strong correlation with GM-EIA (rs=0.838), indicating its potential for clinical use.